The world’s first proven trillion-dose exosome system.It is safe, utilizing a closed system that can be prepared in a clinical setting without requiring special equipment, and it is classified as a CE-certified medical device.
It offers the ability to administer safe, high-dose injections that are free from the risks and usage restrictions associated with low-dose plant- or animal-derived exosome products.
1,000 $
We have eliminated the need for high-tech and expensive equipment to produce exosomes. All you need to produce trillions of exosomes from your own blood is our kit and a centrifuge.
It offers a high platelet recovery rate with 4x 10ml sodium citrate included PRP Tubes.
Platelet activation is triggered with the specially designed Relyzer blade.
And most importantly, the 2x10ml Advanced PRX Tube, with its patented, specially textured inner surface, facilitates exosome release.
All you need to do is collect and inject trillions of exosomes.
NanoSight Analysis
In 10cc Totally 5,78 Trillions of Exosome
Average size : 120nm +/-15
Vesicle measurements were performed using the NanoSight NS300. (Measurements were performed at Yeditepe University.)
Flow Cytometry Analysis
Not every vesicle is an exosome. The most accurate results are obtained by characterizing exosomes using flow cytometry.
Viability: 98.9% (7 AAD)
Nearly all are platelet-derived: Over 98%: CD41, CD61, CD9
Immunophenotypic measurements were performed using Beckman Coulter DxFLEX Flow Cytometry system, and the evaluation was completed with the CytExpert DFLEX software program. (Measurements were done at the Private Deren Laboratory.)
Leukocyte-derived Exosomes: Negligible: 0.3% (CD45)
At the same time, there are almost no leukocyte-derived exosomes, which are also scarce at 0.3%.
CD9 (Platelet): 99.6%
CD45 (Pan Leukocyte Marker): 0.3%
CD41 (Platelet GPIIb, IIb Integrin): 99.4%
CD61 (Platelet glycoprotein GPIIIa): 98.6%
CD81 (Target for anti-proliferative antigen 1 [TAPA-1]): 98.5%
7 AAD: 98.9%
Where is it used?
Autologous therapy can be used anywhere where platelet-rich
plasma is used as a treatment. Moreover, it is much more active and
has a much higher dose.
Most Common Indications:
It can achieve the results obtained with PRP in three sessions in just one session.
It plays an important role in increasing the vascularization of hair follicles.
It increases collagen and elastin synthesis by providing genetic activation at the cellular level.
While stimulants such as laser and dermapen are required in combination with PRP, autologous exosomes do not require stimulants to be active.
Its regenerative effect at the cellular level can initiate cartilage regeneration at the right stages. It is effective in tendon injuries.
It is very effective in relieving pain with its high anti-inflammatory effect.
It has demonstrated its effectiveness in wound treatments by increasing microvascularization and tissue signalization.
It is effective in treating corneal ulcers, dry eye syndrome and delaying retinitis pigmentosa problems.
It is effective in wound healing in this area due to its effect on hard and soft tissue.
